FUNDAMENTALS · Fundamentals · CH Healthcare

ADC Therapeutics (ADCT) Fundamentals 2026 — Revenue Analysis | SniperIQ

ADC Therapeutics (ADCT) is a CH-listed Healthcare company in Biotechnology with a market capitalization of

55M, trading at
.22 on the NYSE. This SniperIQ fundamentals page covers ADC Therapeutics's valuation, profitability (net margin -173.0%), revenue ($81M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
55M
Net Margin-173.0%
Revenue (FY25)$81M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is ADC Therapeutics's market cap?

ADC Therapeutics (ADCT) has a market capitalization of approximately

55M, trading at
.22 on the NYSE. Market cap moves with the live share price.

How profitable is ADC Therapeutics?

ADC Therapeutics runs a net profit margin of -173.0%, a gross margin of 90.7%, and an operating margin of -148.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does ADC Therapeutics generate?

ADC Therapeutics reported revenue of $81M for fiscal year 2025, with net income of -

43M and earnings per share (EPS) of -1.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does ADC Therapeutics pay a dividend?

ADC Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is ADC Therapeutics financially healthy?

ADC Therapeutics carries a debt-to-equity ratio of -0.54x and a current ratio of 4.09x, with a market beta of 1.88. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is ADC Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For ADC Therapeutics (ADCT) the key facts are: market cap

55M, revenue $81M, 52-week range 0.78-4.98. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track ADC Therapeutics's full fundamentals live

Get ADC Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Orthocell (OCC) fundamentals · Actinogen Medical (ACW) fundamentals · Optiscan Imaging (OIL) fundamentals · EMVision Medical Devices (EMV) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons